Answers are grounded in this paper and cite their sources.
Chronic anal fissure (CAF) causes significant quality of life impairment. Botulinum A toxin (Botox; brand name Dysport, Ipsen Biopharmaceuticals Inc.) injection into the anal sphincter is an established treatment. In New Zealand and Australia, anal Botox injection is often performed under general anesthesia (GA). The primary aim of the current study was to investigate the efficacy of treating CAF with outpatient anal Botox injection without sedation. The secondary aims were to assess its safety and cost-saving potential. A retrospective audit was conducted at a tertiary public hospital between 2011 and 2013. Patients diagnosed with CAF underwent an anorectal examination and received Botox injection in the outpatient clinic. Demographic and comorbidity data were recorded. Patients were followed by telephone or clinic visit after 2 weeks, and then, as required. Success was defined as symptom resolution or patient-reported improvement such that no further treatment was required. A total of 163 patients were treated (median age: 40.5 years; range: 15–88 years). After 1 Botox injection, 106 patients (65.0%) reported satisfactory symptom resolution at follow-up. After 1 to 2 injections, 134 patients (82.2%) achieved symptom resolution. A total of 29 patients (17.8%) reported refractory symptoms despite 2 injections, and they were offered a third injection in the outpatient clinic or an examination under GA. No major complications were reported. Botox injections can effectively treat CAF in an outpatient setting, with similar success rates to injection under GA. Widespread adoption of this technique could lead to significant cost savings in healthcare resources.
No takes yet. Share an insight, caveat, or question.
Khatri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: